Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +0.40%19 3-Year RORE % is 51.92 as of Jun. 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, Anlon Healthcare ranks better than 83.84% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Anlon Healthcare's 3-Year RORE % for the quarter that ended in Jun. 2026 was 51.92%.
The industry rank for Anlon Healthcare's 3-Year RORE % or its related term are showing as below:
NSE:AHCL's 3-Year RORE % is ranked better than 83.84% of 947
companies
in the Drug Manufacturers industry
Industry Median: 2.78
vs NSE:AHCL: 51.92
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Anlon Healthcare 3-Year RORE % Related Terms
Anlon Healthcare 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Anlon Healthcare (NSE:AHCL) has a 3-Year RORE % of 51.92 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Anlon Healthcare and its competitors. According to the industry distribution chart, Anlon Healthcare ranks #153 out of 947 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Anlon Healthcare's 3-Year RORE % too high?
Anlon Healthcare's current 3-Year RORE % is 51.92. The Drug Manufacturers industry median 3-Year RORE % is 2.78. Anlon Healthcare's value of 51.92 is 1767.6% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #153 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #153 out of 947 companies for 3-Year RORE %. This places Anlon Healthcare in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 2.78. Anlon Healthcare's value of 51.92 is 1767.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.78, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current 3-Year RORE % of 51.92 is 1767.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current 3-Year RORE % is 51.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current 3-Year RORE % of 51.92. The current 3-Year RORE % is 51.92 and 1767.6% above the Drug Manufacturers industry median of 2.78. Anlon Healthcare's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current 3-Year RORE % is 51.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
19GF Score
Get the complete analysis for NSE:AHCL
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
